2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma
Why now
Thesis: Early trispecific data supports Innovent oncology pipeline
Catalyst to watch: Mature Phase 1 efficacy and safety data
Main risk: Early data may not replicate in larger trials
Why it matters
Early trispecific antibody data in myeloma could validate a pipeline asset for Innovent.
Details
SAN FRANCISCO and SUZHOU, China, Sept. 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines for the treatment of oncology, autoimmune,...
Sources
- prnewswire · 2026-09-29 07:45 UTC